HD-OPM Archive
Topics › LDL, ApoB & lipid panel

Every LDL-lowering method lowers cardiac risk in proportion to the LDL reduction achieved

Louis Nervegna · Dec 08, 2024 · ♥ 17 reactions · 5 comments · original Facebook post
LDL, ApoB & lipid panelPCSK9, ezetimibe & newer drugsStatins
AI summary & key facts

Louis shares a chart (originally from Dr. Daniel Chong) combining many trials of different LDL-lowering interventions. Risk reduction scales with the absolute LDL decrease regardless of mechanism: the two PCSK9 inhibitor trials lowered LDL ~1.9 mmol/L (76 mg/dL) with a more than 50% risk reduction versus placebo.

What you see here is a collection of results from a wide variety of clinical trials using a wide variety of methods to lower LDL.

Note:

The x-axis shows the difference in LDL between the treatment and control groups. It is the amount that the particular intervention lowered LDL by, on average.

1mmol/L of LDL converts to around 40mg/dL.

The y-axis shows the reduction in risk, relative to taking a placebo.

For example, the two PCSK9 inhibitor trials lowered LDL by about 1.9mmol/L (76mg/dL), which corresponds to a risk reduction relative to placebo of over 50%.

The key thing to notice:

Every method has a distinctly different mechanism of action— relative to the other options— for how it gets the LDL to come down.

And yet, despite that, the degree of effect on reducing risk for major cardiac events like heart attacks is essentially the same for each one, based specifically on the amount that LDL is lowered.

In other words, whatever is used, from diet to various types of drugs, if LDL goes down, risk goes down in response.

Note: This post comes from Dr. Daniel Chong (Vital Human- Dr. Daniel Chong). I have basically copied his post on this from another group.

Reference for chart:

PaperAssociation Between Lowering LDL C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta analysisresearchgate.net

#statinrctsHD #ldlrctsHD

Research cited

← newer: 'The Cholesterol Deniers': Proto Magazine article on statin older: Harvard summary: protein source matters for diabetes; red me →